Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
ACS Applied Bio Materials|January 14, 2025
Ru<sup>III</sup>-Morpholine-Derived Thiosemicarbazone-Based Metallodrugs: Lysosome-Targeted Anticancer AgentsMonalisa Mohanty, Sanchita Das, Pratikshya Das Pattanayak, et al.
Dalton Transactions (Cambridge, England : 2003)|March 23, 2026
Spin dynamics and long phase-memory times in structurally distinct non-oxido vanadium(IV) complexes with rigid ligand frameworks relevant to molecular qubitsOluseun Akintola, Sudhir Lima, Michael Seifert, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|January 4, 2023
Ruthenium(II)-Dithiocarbazates as Anticancer Agents: Synthesis, Solution Behavior, and Mitochondria-Targeted Apoptotic Cell DeathGurunath Sahu, Sushree Aradhana Patra, Sudhir Lima, et al.
Journal of Inorganic Biochemistry|May 5, 2022
Dithiocarbazate based oxidomethoxidovanadium(V) and mixed-ligand oxidovanadium(IV) complexes: Study of solution behavior, DNA binding, and anticancer activityGurunath Sahu, Sushree Aradhana Patra, Monalisa Mohanty, et al.
Chemistry, an Asian Journal|March 13, 2025
Hydrazonate-Based Copper(II) Metallodrugs: Insights into Solution Behavior, G-Quadruplex DNA Interaction, and Anticancer PotentialMonalisa Mohanty, Sudhir Lima, Pratikshya Das Pattanayak, et al.
Journal of Inorganic Biochemistry|May 17, 2022
Evaluation of DNA/BSA interaction and in vitro cell cytotoxicity of μ<sub>2</sub>-oxido bridged divanadium(V) complexes containing ONO donor ligandsSushree Aradhana Patra, Atanu Banerjee, Gurunath Sahu, et al.
Journal of Inorganic Biochemistry|May 22, 2022
New mixed ligand oxidovanadium(IV) complexes: Solution behavior, protein interaction and cytotoxicitySudhir Lima, Atanu Banerjee, Gurunath Sahu, et al.
Pageof 2